OsteoGeneX Inc.
http://www.osteogenex.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From OsteoGeneX Inc.
Ligand Buys Into Ongoing Partnerships With Icagen Deal
Ligand gets ongoing drug development collaborations with Roche and CFF, six novel preclinical compounds and sodium ion channel technology platform capabilities in acquiring Icagen’s North Carolina operations.
Amgen Puts Evenity Filing Back On Track With TIMI Cardiovascular Risk Review
As Amgen’s main hope for extending its bone health franchise, romosozumab faces a second review at the FDA with a fuller dataset and an external analysis of cardiovascular risk.
Super-Specialist CROs: Commercializing Pharma R&D Expertise
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Astellas, Chromocell In Pain Pact Worth $515m-plus
Astellas will pay Chromocell $15m up front and could spend more than $500m on milestone fees under a license and collaboration agreement for Nav1.7 antagonists, including lead drug candidate CC8464 and backup compounds, for the treatment of neuropathic pain and other conditions.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice